JP2024529070A - Ａｔｒ阻害剤としてのナフチリジン誘導体およびその調製方法 - Google Patents

Ａｔｒ阻害剤としてのナフチリジン誘導体およびその調製方法 Download PDF

Info

Publication number
JP2024529070A
JP2024529070A JP2024507174A JP2024507174A JP2024529070A JP 2024529070 A JP2024529070 A JP 2024529070A JP 2024507174 A JP2024507174 A JP 2024507174A JP 2024507174 A JP2024507174 A JP 2024507174A JP 2024529070 A JP2024529070 A JP 2024529070A
Authority
JP
Japan
Prior art keywords
membered
heterocycloalkyl
compound
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024507174A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529070A5 (enExample
Inventor
シエ，ユリ
リウ，ウェンジョン
チエン，リフゥイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Publication of JP2024529070A publication Critical patent/JP2024529070A/ja
Publication of JP2024529070A5 publication Critical patent/JP2024529070A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024507174A 2021-08-11 2022-08-11 Ａｔｒ阻害剤としてのナフチリジン誘導体およびその調製方法 Pending JP2024529070A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110919812.6 2021-08-11
CN202110919812 2021-08-11
CN202111188963 2021-10-12
CN202111188963.5 2021-10-12
CN202210918443.3 2022-08-01
CN202210918443 2022-08-01
PCT/CN2022/111893 WO2023016529A1 (zh) 2021-08-11 2022-08-11 作为atr抑制剂的萘啶衍生物及其制备方法

Publications (2)

Publication Number Publication Date
JP2024529070A true JP2024529070A (ja) 2024-08-01
JP2024529070A5 JP2024529070A5 (enExample) 2025-08-19

Family

ID=85199870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024507174A Pending JP2024529070A (ja) 2021-08-11 2022-08-11 Ａｔｒ阻害剤としてのナフチリジン誘導体およびその調製方法

Country Status (8)

Country Link
US (1) US20240317741A1 (enExample)
EP (1) EP4385992A4 (enExample)
JP (1) JP2024529070A (enExample)
CN (1) CN117642401A (enExample)
AU (1) AU2022325376A1 (enExample)
CA (1) CA3227336A1 (enExample)
TW (1) TWI831325B (enExample)
WO (1) WO2023016529A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523987A (ja) * 2014-08-04 2017-08-24 バイエル・ファルマ・アクティエンゲゼルシャフト ２−（モルホリン−４−イル）−１，７−ナフチリジン

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729680B2 (en) * 2016-01-14 2020-08-04 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
WO2018153970A1 (en) * 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine
KR20210097124A (ko) * 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
CN116234551A (zh) * 2020-09-27 2023-06-06 南京明德新药研发有限公司 一类1,7-萘啶类化合物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523987A (ja) * 2014-08-04 2017-08-24 バイエル・ファルマ・アクティエンゲゼルシャフト ２−（モルホリン−４−イル）−１，７−ナフチリジン

Also Published As

Publication number Publication date
CA3227336A1 (en) 2023-02-16
EP4385992A1 (en) 2024-06-19
EP4385992A4 (en) 2025-12-03
AU2022325376A1 (en) 2024-02-22
TWI831325B (zh) 2024-02-01
WO2023016529A1 (zh) 2023-02-16
US20240317741A1 (en) 2024-09-26
TW202306955A (zh) 2023-02-16
CN117642401A (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
TWI831325B (zh) 作為atr抑制劑的萘啶衍生物及其製備方法
CN114901661B (zh) 新型K-Ras G12C抑制剂
CN115335379B (zh) 含螺环的喹唑啉化合物
JP2025508192A (ja) Ｋｉｆ１８ａ阻害剤
AU2024358271A1 (en) Fused ring compound and use thereof in kras inhibitor
JP2025523030A (ja) Ｍｙｔ１阻害剤としての化合物
CN116390728B (zh) 喹唑啉衍生物及其制备方法和用途
EP3354647A1 (en) Egfr kinase inhibitor and preparation method and use thereof
US20250059206A1 (en) Fused ring compound acting as shp2 inhibitor
CN115867542B (zh) 新型苯并咪唑化合物
WO2025092773A1 (zh) 作为myt1抑制剂的化合物
EP4714938A1 (en) Hdac1/2 selective inhibitor and use thereof
JP2024547090A (ja) Ｆａｋ阻害剤としての化合物およびその使用
JP2025507732A (ja) Ｆａｋ阻害剤としての化合物およびその使用
CN117295743A (zh) 作为Wee-1抑制剂的吡咯并嘧啶衍生物
TW202146406A (zh) 新型吡嗪化合物
CN117222648B (zh) 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
JP2024544558A (ja) Ｓｒｃ阻害剤としての化合物
CN121517424A (zh) PI3Kα抑制剂及其制备方法和医药用途
CN114907189B (zh) 多酚取代的3-芳基-2-芳基甲基丙烯类化合物及其制备方法和应用
HK40116439A (en) Compound used for egfr protein degradation, and use thereof
WO2026090857A1 (zh) 一种多取代的氨基喹啉类化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250808

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260512